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C
ancer cells proliferate with aban-
don and in defi  ance of the restric-
tions usually placed on dividing 
cells. How do cancer cells—or normal 
dividing cells, for that matter—fuel ram-
pant growth? That’s a question Craig 
Thompson is bent on answering.
Thompson trained in research while 
serving as an MD in the US Navy (1). 
Though he never went to sea, he has made 
waves throughout his career—fi  rst as an 
immunologist with his work on the T cell–
specifi  c signaling receptor CD28 (2, 3), 
then with his lab’s efforts to characterize 
the mechanisms by which Bcl-2 family 
members regulate apoptosis (3, 4), and now 
in the fi  eld of cancer biology investigating 
the metabolic requirements of dividing cells 
(5, 6). Along the way, Thompson has taken 
the helm of research institutes at the Uni-
versity of Chicago and the University of 
Pennsylvania, and is now transitioning to 
president and CEO at Memorial Sloan-
Kettering Cancer Center in New York. We 
caught him fresh off the train from a visit to 
his lab’s future site to talk about the currents 
he’s followed in his career.
ON THE BASE
What did you want to be 
when you were a kid?
I never really thought about 
it. My father was a career 
Coast Guard offi  cer, which 
meant I grew up all over the 
country. One thing you do 
when you’re a military brat is 
that every time you move, 
you have to make new friends 
and integrate yourself into the community. 
My way to do that was to play sports.
What sports did you play?
I played soccer and basketball in high school. 
I was able to go to college because I was re-
cruited to play sports. Some schools recruit-
ed me to play soccer, but I went to Dartmouth 
to join their whitewater kayaking team. I got 
my varsity letter in whitewater kayaking, 
and I tried out for both the national and 
Olympic teams, but I didn’t make either.
What did you study in college?
During school I took science courses. They 
were the easiest things to get good grades 
in, because I liked them. In fact, I had a 
huge falling out with the soccer coach at 
Dartmouth because I wouldn’t give up my 
lab courses, which he thought were hurting 
my soccer career. So I quit the soccer team, 
took the lab courses and realized that I 
might like to become a scientist. The only 
person I had ever met who made a living 
using their science knowledge was the base 
doctor when I was growing up, so I decided 
to go to medical school.
Why did you enlist in the navy after 
medical school?
The navy paid my way through medical 
school; otherwise I wouldn’t have been 
able to afford it. In exchange for that, 
when I fi  nished my medical degree, I went 
into the navy for eight years—I completed 
the regular four-year enlistment, then re-
upped. My fi  rst assignment 
was at a very cool place, the 
Naval Blood Research Lab-
oratory. It’s the laboratory 
that fi  gured out, starting in 
the late ’40s, how to freeze 
and thaw blood cells and 
still have them function. I 
was assigned to work on a 
new blood particle that peo-
ple were just starting to take 
seriously in the clinic: the 
platelet. I worked on meas-
uring platelets and fi  guring out whether 
we could cryopreserve them.
My next job in the navy was to work as 
a general medical offi  cer at the National 
Naval Medical Center and as a researcher 
at the Naval Medical Research Institute, 
which is directly across the street from the 
NIH. I worked for a guy named Irwin Scher 
who ran a very good immunology lab, and 
I learned all my immunology there.
CAREER CRUISE
What brought you to studying cancer 
biology and metabolism?
A central aim of my lab has been to under-
stand how cells are licensed to divide in 
two, and how they are permitted to sur-
vive long term. Lymphocytes (T and B 
cells) are a great setting in which to study 
this question because they proliferate 
throughout their lives, but their proliferation 
and survival is tightly controlled. T cells, 
for example, require two specifi  c signals 
to expand their populations. One signal 
comes from the T cell receptor, and the 
other signal comes from a class of pro-
teins called costimulatory receptors, the 
most famous of which is CD28. In collab-
oration with Carl June, I’ve studied CD28 
since I started my fi  rst lab at the Univer-
sity of Michigan. Recently, we found that 
CD28, through the PIP3 kinase/AKT path-
way, instructs cells to take up and metabo-
lize glucose, in direct proportion to the 
magnitude of CD28 signal transduction.
We found that CD28-stimulated T 
cells switch from using primarily oxida-
tive metabolism to using glycolytic metabo-
lism as they enter exponential growth. 
Glycolysis is thought of as a wasteful 
form of energy utilization, because the 
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vast majority of the glucose taken up is 
secreted as lactate instead of being fully 
catabolized into CO2 and ATP. So we 
asked, why is it that cells, when engaged 
in maximal proliferation, prefer to use 
glycolytic metabolism?
Why is that?
Glycolytic metabolism breaks down glu-
cose into the building blocks for growth: 
the precursors for the nucleotides, non-
essential amino acids and, critically, lipids   
that cells need to replicate their genome, 
synthesize proteins, and build membrane 
to surround themselves with as they grow. 
As long as you have an abundant supply of 
all the intermediates in the glycolytic path-
way and you don’t catabolize those to CO2, 
you can use them to grow.
Cells can also use another fuel source: 
glutamine. Glutamine plays an essential 
role, fi  rst, in the ability to produce enough 
NADPH to fuel macromolecular synthesis. 
Secondly, it allows glucose-derived carbon 
to be diverted into serine, glycine, and ri-
bose biosynthesis. And third—and we 
were not the fi  rst to discover this—glu-
tamine is essential for the uptake of non-
essential amino acids. Except for ribose 
biosynthesis, glutamine can do everything 
that glucose can. It only has one conse-
quence to the cell, which we’re starting to 
think of exploiting for cancer therapy, which 
is that it produces ammonia as a byproduct.
TARGET IN SIGHT
How does a cancer cell behave 
differently than a normal cell with 
regard to metabolism?
We think that metazoan cells, in coming 
together in large collections as multicel-
lular organisms, have given up the cell-
autonomous ability to continuously take 
up nutrients from their environment. Even 
though they may be surrounded by nutri-
ents all the time, their ability to take up 
and capture nutrients is regulated by sig-
nal transduction. The corollary to that is if 
your signal transduction is stuck “on” all 
the time, you’ll pick up more nutrients than 
you know what to do with. We believe that 
is what oncogenic transformation primarily 
does in most human cancers. It fi  xes “on” 
the ability to scavenge glucose, glutamine, 
or both from the environment. For example, 
we have shown that Myc transformation 
makes cells glutamine addicted.
Most transforming events are pro-apop-
totic because when you turn on a pathway 
that instructs the building of 
macromolecules without the 
resources to do it, you create a 
bioenergetic crisis for a cell. 
The only way the cell can 
deal with that is either to eat 
itself by auto  phagy, or to rec-
ognize the problem and initi-
ate apoptosis. Therefore, we 
think a productive cancer cell 
has to acquire a mutation in 
what we call the fuel-sensing 
pathways. In addition, we 
have proposed that mutations 
in pathways that render nutri-
ent uptake cell autonomous arise fi  rst in 
almost every successful cancer. After that, 
other mutations may accumulate because 
the extra electrons produced during the 
catabolism of excess nutrients generate 
reactive oxygen species that damage DNA.
What will be your focus once you’re set 
up at Memorial Sloan-Kettering?
We’re looking at whether acquiring muta-
tions that render nutrient uptake cell autono-
mous is a part of what transformation and 
cancer are really about, and whether muta-
tions in, or altered regulation of, metabolic 
enzymes might represent new clinical tar-
gets. For example, we’re working on a 
protein called isocitrate dehydrogenase, 
which is one of the three human enzymes 
that produce NADPH. It was shown about 
two years ago to be mutated in a small set 
of patients with glioblastoma, and we started 
looking at why it was mu-
tated. We found that the mu-
tation does not cause a loss of 
enzyme function, as was 
previously  thought, but in 
fact creates a new enzyme 
activity that produces a new 
metabolic product that’s not 
normally part of our metabo-
lism, called 2-hydroxyglu-
tarate. We think that’s the 
fi  rst neomorphic enzyme that 
has ever been described in 
human disease.
How is it used by cancer cells?
For that answer you’ll have to read the 
paper we’re writing right now!
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Thompson is taking the long view on cell 
metabolism.
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Thompson, discussing what heading to take 
in the lab.